Get the Stockscreener App
25.16
1.94%
0.48
After Hours:
25.16
Denali Therapeutics Inc stock is traded at $25.16, with a volume of 560.03K.
It is up +1.94% in the last 24 hours and down -3.79% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$24.68
Open:
$25.27
24h Volume:
560.03K
Relative Volume:
0.65
Market Cap:
$3.55B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-23.08
EPS:
-1.09
Net Cash Flow:
$-402.10M
1W Performance:
+3.03%
1M Performance:
-3.79%
6M Performance:
+30.97%
1Y Performance:
+40.25%
1-Day Range:
$24.78
$25.42
1-Week Range:
$23.80
$25.77
52-Week Range:
$14.56
$33.33
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8548
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
25.16 | 3.55B | 340.81M | -419.65M | -402.10M | -1.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Denali Therapeutics Inc. (NASDAQ:DNLI) Stake Lifted by Victory Capital Management Inc. - MarketBeat
Objective long/short (DNLI) Report - Stock Traders Daily
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Consensus PT from Analysts - MarketBeat
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging - MSN
Denali Therapeutics updates bylaws, aligns with SEC rules - Investing.com India
Denali Therapeutics updates bylaws, aligns with SEC rules By Investing.com - Investing.com UK
Denali Therapeutics (NASDAQ:DNLI) Trading Down 8.3%Here's What Happened - MarketBeat
Denali Has A Neurodegenerative Edge Despite Market Skepticism (NASDAQ:DNLI) - Seeking Alpha
Los Angeles Capital Management LLC Trims Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely - Yahoo Finance
State of New Jersey Common Pension Fund D Sells 25,613 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Capital Research Global Investors Expands Stake in Denali Therap - GuruFocus.com
FMR LLC Expands Stake in Denali Therapeutics Inc - GuruFocus.com
BofA raises Denali Therapeutics target to $34 on BLA plans By Investing.com - Investing.com Canada
Denali Therapeutics executive sells shares worth $465,286 - Investing.com India
Denali Therapeutics executive sells shares worth $465,286 By Investing.com - Investing.com Canada
Baillie Gifford & Co. Sells 417,709 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Principal Financial Group Inc. Increases Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics stock soars to 52-week high of $32.17 - Investing.com India
Denali Therapeutics stock soars to 52-week high of $32.17 By Investing.com - Investing.com Canada
Learn to Evaluate (DNLI) using the Charts - Stock Traders Daily
Denali Therapeutics (NASDAQ:DNLI) Reaches New 12-Month HighStill a Buy? - MarketBeat
Wedbush Cuts Earnings Estimates for Denali Therapeutics - Defense World
Brokers Issue Forecasts for DNLI Q1 Earnings - MarketBeat
HC Wainwright Has Bearish Forecast for DNLI FY2024 Earnings - MarketBeat
Equities Analysts Offer Predictions for DNLI FY2024 Earnings - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Denal - GuruFocus.com
HC Wainwright Issues Pessimistic Forecast for DNLI Earnings - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Given "Buy" Rating at HC Wainwright - MarketBeat
Denali Therapeutics earnings missed by $0.03, revenue topped estimates - Investing.com UK
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Denali Therapeutics director Vicki Sato sells $83,375 in stock - Investing.com India
Denali Therapeutics director Vicki Sato sells $83,375 in stock By Investing.com - Investing.com UK
abrdn plc Sells 209,356 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Thinking about buying stock in QuickLogic, Ventyx Biosciences, D - GuruFocus.com
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - Yahoo Finance
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.22 Average Price Target from Analysts - MarketBeat
Zacks Research Issues Pessimistic Forecast for DNLI Earnings - MarketBeat
Denali Therapeutics CEO Ryan Watts sells shares worth $1.1 million - Investing.com
Insider Selling: Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Sells 40,000 Shares of Stock - MarketBeat
(DNLI) Investment Analysis and Advice - Stock Traders Daily
The five-year returns have been notable for Denali Therapeutics (NASDAQ:DNLI) shareholders despite underlying losses increasing - Simply Wall St
Denali Therapeutics Inc (DNLI) stock on the rise: An overview - US Post News
Denali Therapeutics Inc (DNLI)’s Market Momentum: Closing Strong at 26.83, Down -4.18 - The Dwinnex
This trade activity should not be overlooked: Denali Therapeutics Inc (DNLI) - SETE News
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Denali Therapeutics Inc Stock (DNLI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schenkein David P | Director |
Nov 11 '24 |
Option Exercise |
18.00 |
47,165 |
848,970 |
68,661 |
| Schenkein David P | Director |
Nov 11 '24 |
Sale |
32.51 |
59,441 |
1,932,665 |
9,220 |
| Schuth Alexander O. | COFO and Secretary |
Nov 07 '24 |
Option Exercise |
5.28 |
15,558 |
82,146 |
193,624 |
| Schuth Alexander O. | COFO and Secretary |
Nov 07 '24 |
Sale |
29.91 |
15,558 |
465,286 |
178,066 |
| SATO VICKI L | Director |
Nov 07 '24 |
Sale |
30.00 |
1,020 |
30,600 |
111,056 |
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):